Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
暂无分享,去创建一个
S. Wilhelm | M. Lynch | Christopher A. Carter | D. Wilkie | Angela McNabola | Charles Chen | Xiaomei Zhang | Yichen Cao | Li Liu | Mark Lynch | Scott Wilhelm | Li Liu | Yichen Cao | Charles Chen | Xiaomei Zhang | Angela McNabola | Dean Wilkie | Christopher Carter | Angela Mcnabola
[1] M. Santoro,et al. BAY 43-9006 inhibition of oncogenic RET mutants. , 2006, Journal of the National Cancer Institute.
[2] M. Atkins,et al. The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. , 2006, Cancer research.
[3] S. Wilhelm,et al. Hepatocellular Carcinoma Model PLC / PRF / 5 Tumor Angiogenesis , and Induces Tumor Cell Apoptosis in Sorafenib Blocks the RAF / MEK / ERK Pathway , Inhibits , 2006 .
[4] M. Peck-Radosavljevic,et al. Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy. , 2006, Journal of hepatology.
[5] P. Galle,et al. Mcl-1 is an anti-apoptotic factor for human hepatocellular carcinoma. , 2006, International journal of oncology.
[6] W. Kolch. Coordinating ERK/MAPK signalling through scaffolds and inhibitors , 2005, Nature Reviews Molecular Cell Biology.
[7] P. Dent,et al. Apoptosis Induced by the Kinase Inhibitor BAY 43-9006 in Human Leukemia Cells Involves Down-regulation of Mcl-1 through Inhibition of Translation* , 2005, Journal of Biological Chemistry.
[8] G. Gores,et al. The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006 , 2005, Oncogene.
[9] Walter Kolch,et al. Role of the Kinase MST2 in Suppression of Apoptosis by the Proto-Oncogene Product Raf-1 , 2004, Science.
[10] P. Tan,et al. Extracellular signal-regulated kinase induces cyclin D1 and Cdk-2 expression and phosphorylation of retinoblastoma in hepatocellular carcinoma. , 2004, International journal of oncology.
[11] J. Dufour,et al. Angiogenesis and hepatocellular carcinoma. , 2004, Journal of hepatology.
[12] Josepa Ribes,et al. Primary liver cancer: worldwide incidence and trends. , 2004, Gastroenterology.
[13] Richard Marais,et al. The RAF proteins take centre stage , 2004, Nature Reviews Molecular Cell Biology.
[14] D. Auclair,et al. BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.
[15] C. Marshall,et al. B-RAF is a therapeutic target in melanoma , 2004, Oncogene.
[16] R. Schnellmann,et al. Identification of Caspase-Independent Apoptosis in Epithelial and Cancer Cells , 2004, Journal of Pharmacology and Experimental Therapeutics.
[17] S. S. Koh,et al. Over-expression of c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma. , 2004, Hepatology research : the official journal of the Japan Society of Hepatology.
[18] C. Schmidt,et al. Multiple anticancer effects of blocking MEK-ERK signaling in hepatocellular carcinoma. , 2004, Journal of the American College of Surgeons.
[19] T. T. Nguyen,et al. Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: Its role in tumor progression and apoptosis , 2003, BMC gastroenterology.
[20] M. Barbacid,et al. RAS oncogenes: the first 30 years , 2003, Nature Reviews Cancer.
[21] F. Sommerer,et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma , 2003, Gut.
[22] J. Węsierska‐Gądek,et al. CELLTITER-GLO ® ASSAY: APPLICATION FOR ASSESSING DIRECT CYTOTOXICITY AND FOR DETERMINING CELL PROLIFERATION , 2003 .
[23] W. Kolch,et al. Extracellular signal regulated kinase (ERK)/mitogen activated protein kinase (MAPK)-independent functions of Raf kinases. , 2002, Journal of cell science.
[24] S. Fan,et al. Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] C. Der,et al. Ras and Rho regulation of the cell cycle and oncogenesis. , 2001, Cancer letters.
[26] C. Pritchard,et al. MEK kinase activity is not necessary for Raf‐1 function , 2001, The EMBO journal.
[27] E. Wagner,et al. Embryonic lethality and fetal liver apoptosis in mice lacking the c‐raf‐1 gene , 2001, The EMBO journal.
[28] I. McKillop,et al. Increased MAPK expression and activity in primary human hepatocellular carcinoma. , 1997, Biochemical and biophysical research communications.
[29] K. Shirabe,et al. Results of 280 liver resections for hepatocellular carcinoma. , 1996, Archives of surgery.
[30] D. Woodfield. Hepatocellular carcinoma. , 1986, The New Zealand medical journal.
[31] A. Wyllie,et al. Cell death: the significance of apoptosis. , 1980, International review of cytology.